Download PDF
Exp Clin Endocrinol Diabetes
DOI: 10.1055/a-2280-3742
Article

Association Between Liver Fibrosis Score and Diabetic Kidney Disease: A Retrospective Cross-Sectional Study of Hospitalized Patients

Jie Zhang   ‡
1   Department of Endocrinology and Metabolism, First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, 330006, People’s Republic of China
,
Shen Chen‡   ‡
4   Queen Mary School, Medical College, Nanchang University, Nanchang 330006, China
,
Zhendong Tian
4   Queen Mary School, Medical College, Nanchang University, Nanchang 330006, China
,
Jiarui Cao
4   Queen Mary School, Medical College, Nanchang University, Nanchang 330006, China
,
Yijie Jiao
5   The Third Clinical Medical School, Medical College, Nanchang University, Nanchang 330006, China
,
Bangqi Wang
4   Queen Mary School, Medical College, Nanchang University, Nanchang 330006, China
,
Shenghui Feng
4   Queen Mary School, Medical College, Nanchang University, Nanchang 330006, China
,
Zhanpeng Luo
4   Queen Mary School, Medical College, Nanchang University, Nanchang 330006, China
,
Qingfang Zhang
4   Queen Mary School, Medical College, Nanchang University, Nanchang 330006, China
,
Yuanyuan Deng
1   Department of Endocrinology and Metabolism, First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, 330006, People’s Republic of China
,
Wei Cai
6   Department of Medical Genetics and Cell biology, Medical College of Nanchang University, Nanchang, 330006, People’s Republic of China
,
Jixiong Xu
1   Department of Endocrinology and Metabolism, First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, 330006, People’s Republic of China
2   Jiangxi Clinical Research Center for Endocrine and Metabolic Disease, Nanchang, Jiangxi, 330006, People’s Republic of China
3   Jiangxi Branch of National Clinical Research Center for Metabolic Disease, Nanchang, Jiangxi, 330006, People’s Republic of China
› Author Affiliations Funding Information Provincial Science and Technology Innovation Base Plan-Provincial Clinical Medical Research Center — 2020BCG74001 National Natural Science Funds of China — 82160140 Key research and development projects of the Social Development Department of Jiangxi Provincial Department of Science and Technology — 20201BBG71006 Construction of scientific and technological Innovation base- Clinical medical Research Center — 20221ZDG02011 This study was supported by grants from the Provincial Science and Technology Innovation Base Plan-Provincial Clinical Medical Research Center (grant no. 2020BCG74001), Construction of Scientific and Tet_chnological Innovation base-Clinical Medical Research Center (grant no. 20221ZDG02011), Key research and development projects of the Social Development Department of Jiangxi Provincial Department of Science and Technology (grant no. 20201BBG71006) and National Natural Science Funds of China (grant no. 82160140).
› Further Information
Also available at
    Permissions and Reprints

Abstract

Objectives To investigate the association between liver fibrosis score and diabetic kidney disease (DKD) in type 2 diabetes mellitus (T2DM).

Methods A total of 897 hospitalized patients with T2DM were included in this study. Each patient completed DKD screening. Logistic regression analysis was used to assess the predictive value of non-alcoholic fatty liver disease fibrosis score (NAFLD-FS) and fibrosis-4 (FIB-4) for the occurrence of DKD and risk for DKD progression, respectively.

Results The prevalence of DKD and risk for its progression significantly increased with increasing NAFLD-FS risk category. DKD prevalence also increased with increasing FIB-4 risk category. Multivariate logistic regression analysis showed that the “high-risk” NAFLD-FS had a significantly higher risk of DKD (odds ratio [OR]: 1.89, 95% confidence interval [CI]: 1.16–3.08) and risk for DKD progression (OR: 2.88, 95% CI: 1.23–6.78), and the “intermediate-risk” FIB-4 had a significantly higher risk of DKD (OR: 1.41, 95% CI: 1.00–1.98). Subgroup analysis showed that the association between NAFLD-FS and FIB-4 and DKD was significant in the female subgroup, whereas the association between the “high-risk” NAFLD-FS and risk for DKD progression was significant in the male subgroup.

Conclusions NAFLD-FS and FIB-4 are strongly associated with DKD and risk for DKD progression in patients with T2DM. Additionally, sexual dimorphism exists in this association.

Keywords

non-alcoholic fatty liver disease fibrosis score - fibrosis-4 - diabetic kidney disease - type 2 diabetes mellitus

‡ These authors contributed equally to this work: Jie Zhang, Shen Chen


Supplementary Material



Publication History

Received: 15 November 2023
Received: 24 February 2024

Accepted: 28 February 2024

Article published online:
10 April 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Sabanayagam C, Chee ML, Banu R. et al. Association of diabetic retinopathy and diabetic kidney disease with all-cause and cardiovascular mortality in a multiethnic Asian population. JAMA Netw Open 2019; 2: e191540
    PubMedGoogle Scholar
  • 2 Ren J, Liu D, Li G. et al. Prediction and risk stratification of cardiovascular disease in diabetic kidney disease patients. Front Cardiovasc Med 2022; 9: 923549
    PubMedGoogle Scholar
  • 3 Bansal N. Evolution of cardiovascular disease during the transition to end-stage renal disease. Semin Nephrol 2017; 37: 120-131
    PubMedGoogle Scholar
  • 4 Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: Effects on the cardiovascular system. Circulation 2007; 116: 85-97
    PubMedGoogle Scholar
  • 5 Xu J, Shi X, Pan Y. The association of aspartate aminotransferase/alanine aminotransferase ratio with diabetic nephropathy in patients with type 2 diabetes. Diabetes Metab Syndr Obes 2021; 14: 3831-3837
    PubMedGoogle Scholar
  • 6 Wu Y, Liu F. Aspartate aminotransferase to alanine aminotransferase ratio and the risk of diabetic nephropathy progression in patients with type 2 diabetes mellitus: A biopsy-based study. J Diabetes Complications 2022; 36: 108235
    PubMedGoogle Scholar
  • 7 Targher G, Byrne CD. Non-alcoholic fatty liver disease: An emerging driving force in chronic kidney disease. Nat Rev Nephrol 2017; 13: 297-310
    PubMedGoogle Scholar
  • 8 Chalasani N, Younossi Z, Lavine JE. et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology . 2012; 142: 1592-1609
    PubMedGoogle Scholar
  • 9 Angulo P, Bugianesi E, Bjornsson ES. et al. Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 2013; 145: 782-789
    CrossrefPubMedGoogle Scholar
  • 10 Xiao G, Zhu S, Xiao X. et al. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: A meta-analysis. Hepatology 2017; 66: 1486-1501
    CrossrefPubMedGoogle Scholar
  • 11 Wen X, Zhou X, Chen D. et al. Association between non-alcoholic fatty liver disease and diabetes-related microvascular complications: A retrospective cross-sectional study of hospitalized patients. Endocr Pract 2022; 28: 304-309
    PubMedGoogle Scholar
  • 12 Sun Y, Hong L, Huang Z. et al. Fibrosis risk in nonalcoholic fatty liver disease is related to chronic kidney disease in older type 2 diabetes patients. J Clin Endocrinol Metab 2022; 107: e3661-e3669
    PubMedGoogle Scholar
  • 13 Levey AS, Stevens LA, Schmid CH. et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-612
    CrossrefPubMedGoogle Scholar
  • 14 Stevens PE, Levin A. Evaluation and management of chronic kidney disease: Synopsis of the kidney disease: Improving global outcomes 2012 clinical practice guideline. Ann Intern Med 2013; 158: 825-830
    CrossrefPubMedGoogle Scholar
  • 15 McPherson S, Hardy T, Dufour JF. et al. Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis. Am J Gastroenterol 2017; 112: 740-751
    CrossrefPubMedGoogle Scholar
  • 16 Targher G, Lonardo A, Byrne CD. Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus. Nat Rev Endocrinol 2018; 14: 99-114
    PubMedGoogle Scholar
  • 17 Morikawa H, Mano K, Horinaka H. et al. Development of non-invasive method for assessment of hepatic steatosis. Ultrasonics 2016; 72: 195-200
    PubMedGoogle Scholar
  • 18 Jin JL, Zhang HW, Cao YX. et al. Liver fibrosis scores and coronary atherosclerosis: Novel findings in patients with stable coronary artery disease. Hepatol Int 2021; 15: 413-423
    PubMedGoogle Scholar
  • 19 Hagstrom H, Talback M, Andreasson A. et al. Ability of noninvasive scoring systems to identify individuals in the population at risk for severe liver disease. Gastroenterology 2020; 158: 200-214
    CrossrefPubMedGoogle Scholar
  • 20 Kuma A, Mafune K, Uchino B. et al. Potential link between high FIB-4 score and chronic kidney disease in metabolically healthy men. Sci Rep 2022; 12: 16638
    PubMedGoogle Scholar
  • 21 Xu HW, Hsu YC, Chang CH. et al. High FIB-4 index as an independent risk factor of prevalent chronic kidney disease in patients with nonalcoholic fatty liver disease. Hepatol Int 2016; 10: 340-346
    PubMedGoogle Scholar
  • 22 Piani F, Melena I, Tommerdahl KL. et al. Sex-related differences in diabetic kidney disease: A review on the mechanisms and potential therapeutic implications. J Diabetes Complications 2021; 35: 107841
    CrossrefPubMedGoogle Scholar
  • 23 Byrne CD, Targher G. NAFLD as a driver of chronic kidney disease. J Hepatol 2020; 72: 785-801
    PubMedGoogle Scholar
  • 24 Kotoku K, Michishita R, Matsuda T. et al. The association between decreased kidney function and FIB-4 Index value, as indirect liver fibrosis indicator, in middle-aged and older subjects. Int J Environ Res Public Health 2021; 18: 6980
    PubMedGoogle Scholar
  • 25 Musso G, De Michieli F, Bongiovanni D. et al. New pharmacologic agents that target inflammation and fibrosis in nonalcoholic steatohepatitis-related kidney disease. Clin Gastroenterol Hepatol 2017; 15: 972-985
    PubMedGoogle Scholar
  • 26 Siragy HM, Carey RM. Role of the intrarenal renin-angiotensin-aldosterone system in chronic kidney disease. Am J Nephrol 2010; 31: 541-550
    PubMedGoogle Scholar
  • 27 Marcuccilli M, Chonchol M. NAFLD and chronic kidney disease. Int J Mol Sci 2016; 17: 562
    PubMedGoogle Scholar